TY - JOUR
T1 - Preventing collateral damage in crohn's disease
T2 - The lémann index
AU - Fiorino, Gionata
AU - Bonifacio, Cristiana
AU - Peyrin-Biroulet, Laurent
AU - Danese, Silvio
PY - 2016/4/1
Y1 - 2016/4/1
N2 - Crohn's disease [CD] is a chronic progressive and destructive condition. Half of all CD patients will develop bowel damage at 10 years. As in rheumatic diseases, preventing the organ damage consequent to CD complications [fistula, abscess, and/or stricture] is emerging as a new therapeutic goal for these patients in clinical practice. This might be the only way to alter disease course, as surgery is often required for disease complications. Similar to the joint damage in rheumatoid arthritis, bowel damage has also emerged as a new endpoint in diseasemodification trials such as the REACT trial. Recently, the Lemann Index [LI] has been developed to measure CD-related bowel damage, and to assess damage progression over time, in order to evaluate the impact of therapeutic strategies in terms of preventing bowel damage. While validation is pending, recent reports suggested that bowel damage is reversible by anti-tumour necrosis factor [TNF] therapy. The Lémann index may play a key role in CD management, and should be implemented in all upcoming disease-modification trials in CD.
AB - Crohn's disease [CD] is a chronic progressive and destructive condition. Half of all CD patients will develop bowel damage at 10 years. As in rheumatic diseases, preventing the organ damage consequent to CD complications [fistula, abscess, and/or stricture] is emerging as a new therapeutic goal for these patients in clinical practice. This might be the only way to alter disease course, as surgery is often required for disease complications. Similar to the joint damage in rheumatoid arthritis, bowel damage has also emerged as a new endpoint in diseasemodification trials such as the REACT trial. Recently, the Lemann Index [LI] has been developed to measure CD-related bowel damage, and to assess damage progression over time, in order to evaluate the impact of therapeutic strategies in terms of preventing bowel damage. While validation is pending, recent reports suggested that bowel damage is reversible by anti-tumour necrosis factor [TNF] therapy. The Lémann index may play a key role in CD management, and should be implemented in all upcoming disease-modification trials in CD.
KW - Bowel damage
KW - Crohn's disease
KW - Imaging
KW - Inflammatory bowel disease
KW - Lémann index
UR - http://www.scopus.com/inward/record.url?scp=84966318368&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84966318368&partnerID=8YFLogxK
U2 - 10.1093/ecco-jcc/jjv240
DO - 10.1093/ecco-jcc/jjv240
M3 - Article
AN - SCOPUS:84966318368
VL - 10
SP - 495
EP - 500
JO - Journal of Crohn's and Colitis
JF - Journal of Crohn's and Colitis
SN - 1873-9946
IS - 4
ER -